Successful Solid-State Circuit Breaker Prototypes Signal Growth Potential
Ideal Power (IPWR) has reached a key milestone in its commercialization strategy, completing all deliverables related to its first design win for solid-state circuit breakers (SSCBs) three months ahead of schedule. The achievement highlights the company’s progress in positioning its patented B-TRAN bidirectional semiconductor power switch as a disruptive technology in power electronics.
Major Partnership Advances B-TRAN Adoption
Ideal Power’s initial design win, announced in December 2024, is tied to a joint development agreement with one of the largest circuit protection equipment manufacturers in Asia. This partner serves key markets, including data centers, renewable energy, energy storage, industrial applications, and utility infrastructure.
As part of the agreement, Ideal Power integrated multiple B-TRAN devices along with the necessary drive circuitry and controls into the customer’s SSCB prototypes. The results were striking—replacing conventional silicon carbide (SiC) components with B-TRAN reduced total losses by more than 60% while adding bidirectional capability. The final prototype met or exceeded all target specifications set by the customer.
By delivering these prototypes early, Ideal Power has enabled its partner to begin marketing the ultra-low-loss circuit breaker product ahead of schedule. The seamless integration of B-TRAN into the existing SSCB design is expected to accelerate time-to-market, creating a competitive advantage for both companies.
Strategic Market Implications
“This design win represents significant validation of B-TRAN as a transformative technology for solid-state circuit breakers,” said Dan Brdar, President and CEO of Ideal Power. “By completing the project a quarter ahead of schedule, our customer will be the first to introduce an ultra-low-loss and inherently bidirectional circuit breaker to a market that has long sought such innovation.”
Brdar emphasized the broader implications of the achievement, noting that the successful launch of the B-TRAN-enabled SSCB product is expected to drive increased engagement with global companies evaluating the technology for circuit protection applications. “A few key design wins could be enough to take us to profitability,” he added.
Significant Revenue Potential
According to the customer’s projections, Ideal Power stands to generate several hundred thousand dollars in revenue from this first B-TRAN-based SSCB product within its first year of sales. By the second year, revenue could exceed $1 million.
The initial product will be marketed to renewable energy and energy storage equipment providers, as well as utility electric distribution network companies. However, the long-term potential extends far beyond this first product. The partner company has expressed interest in developing an entire suite of B-TRAN-enabled SSCBs across multiple voltage and power ratings.
With potential sales of up to one million units per year, this partnership alone could translate into substantial recurring revenue for Ideal Power. Additional applications for B-TRAN-enabled products include data centers, HVAC and lighting systems, electric vehicles, and vehicle-to-grid power conversion.
Positioned for Future Growth
Ideal Power’s early completion of its first B-TRAN design win represents more than just a milestone—it marks a strategic inflection point. The company’s ability to deliver ahead of schedule reinforces confidence in its technology and business execution, while the expanding interest in B-TRAN from major industry players suggests growing momentum.
As the global push for energy efficiency and sustainability continues, Ideal Power’s patented bidirectional semiconductor technology is well-positioned to play a critical role in reshaping power management solutions. With a rapidly expanding pipeline of opportunities, the company is on a path toward significant commercial adoption and long-term profitability.
Read the original press release here
You might like this article:Biotech Stocks Slide as FDA’s Peter Marks Resigns
